Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical Japan Asia Pacific

Alnylam Expands Asian Presence With RNAi License To Japan’s GeneDesign

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

“We’ve just scratched the surface” regarding plans for Asia, Alnylam Director of External Alliances Zimmerman tells “The Pink Sheet” DAILY.

You may also be interested in...



Alnylam Makes Entry Into Chinese RNAi Market

Cambridge, Mass., biopharma adds to Asian presence begun with Japanese licensing deal in October.

Alnylam Makes Entry Into Chinese RNAi Market

Cambridge, Mass., biopharma adds to Asian presence begun with Japanese licensing deal in October.

Alnylam Ends Relationship With Sirna Owner Merck

RNAi firm Alnylam terminated the relationship “to protect our intellectual property,” COO Greene tells “The Pink Sheet” DAILY.

Table

View full table

Topics

Tags:
BioPharmaceutical Japan Asia Pacific
UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By